{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000021","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.985568+00:00","generated_at":"2026-06-07T04:34:18.990490+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS Neurosciences appoints Neil Warma as interim CEO after Gail Farfel departure","bullets":["CEO Gail Farfel separated as President/CEO and Board member effective Dec 30, 2023; will receive severance per agreement.","Neil Warma appointed interim CEO effective Dec 30, 2023; continues as Board member.","Compensation: $250k base salary, up to $400k milestone bonus, and options for 200k shares.","Warma brings neuroscience background; company plans to advance PMN310 in Alzheimer's and seek partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000021","json":"https://secwatch.observer/filing/0001558370-24-000021.json","markdown":"https://secwatch.observer/filing/0001558370-24-000021.md","text":"https://secwatch.observer/filing/0001558370-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/0001558370-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/pmn-20231230x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:34:18.990490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbb78059fb","claim":"Neil Warma was appointed as President and interim Chief Executive Officer at ProMIS Neurosciences Inc..","evidence_excerpt":"Effective December 30, 2023, the Board appointed Neil Warma as President and interim Chief Executive Officer and principal executive officer of the Company (the “Appointment”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/0001558370-24-000021-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e66691c281","claim":"Gail Farfel departed as President and Chief Executive Officer at ProMIS Neurosciences Inc..","evidence_excerpt":"it separated with Gail Farfel, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), in each case, effective as of December 30, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/0001558370-24-000021-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}